This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES to be presented Monday, October 6 at 10am CET Abivax management to hold an analyst and investor call on October 6 at 3pm CET / 9am ET to discu ...

PresentationGood afternoon, everyone. My name is Will Pickering. I cover U.S. biotech at Bernstein. Very pleased to be joined this afternoon by the team from United Therapeutics. I will pass it over to them for some opening remarks, and then we'll have a fireside chat after that.Yes. Thanks, Will. So to start today, we may make some forward-looking statements, and I encourage you to read our latest public filings for any risks and uncertainties associated with those statements. But now I'll pass it off to o ...

ProPhase Labs Inc. (Nasdaq: PRPH), a biotech firm with plans to build a crypto treasury, announced on Sep. 23 that its three COVID-19 testing lab units have filed for reorganization under Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of New Jersey. The bankruptcy action is "strictly" limited to the COVID-19 testing lab units which are collectively owed tens of millions of dollars by insurance companies, the statement read. The goal of the bankruptcy filing is to accelerate recovery ...

PresentationTazeen AhmadBofA Securities, Research Division Good morning to everybody listening in. Welcome to the Bank of America Healthcare Conference. I am Tazeen Ahmad, one of the senior SMID biotech analyst. It is my pleasure to have with me our next presenting company, Ultragenyx. Presenting for Ultragenyx and sitting with me is Eric Crombez, who is Chief Medical Officer. Eric, thanks for making the trip over from the -- [indiscernible] not as far. ...

Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis MartinSeptember 23, 2025 9:15 AM EDT | Source: Defence Therapeutics Inc.Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) FY Conference September 23, 2025 08:00 AM ET Company ParticipantsJeff Poulton - CFOConference Call ParticipantsWilliam Pickering - Senior AnalystWilliam PickeringGood morning, everyone. My name is Will Pickering. I'm Bernstein's U.S. senior analyst for U.S. biotech. Very pleased to be kicking off our 2025 Healthcare Forum with Alnylam Pharmaceuticals. We have Jeff Poulton here, CFO. Jeff, thanks so much for joining us.Jeff PoultonThanks for having us. Good to be here. ...

HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2025 Cell & Gene Meeting on the Mesa Conference taking place October 6-8 in Phoenix, Arizona. “The Cell & Ge ...

ST. LOUIS, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced a major expansion of its Venture Banking team, welcoming a new group of senior bankers, formerly from Silicon Valley Bank, who bring deep expertise across the life sciences and healthcare ecosystem. This strategic move reinforces Stifel’s commitment to supporting innovation-driven companies and investors in sectors such as biotech, diagnostics and tools, medical devices, and healthtech. The new hires are led by M ...

Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launchesCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical ...